Skip to main content

Table 3 Overall survival of patients with gastric cancer

From: The current landscape of gastric cancer and gastroesophageal junction cancer diagnosis and treatment in China: a comprehensive nationwide cohort analysis

 

Stage I

Stage II

Stage III

Stage IV

Total

(N = 7955)

(N = 70333)

(N = 35773)

(N = 57469)

(N = 171530)

No of events, n (%)

312 (3.92)

13,427 (19.09)

9662 (27.01)

28,780 (50.08)

52,181 (30.42)

Median OS, months, 95% CI

79.18 (79.18–80.46)

58.12 (55.92–60.62)

33.48 (32.76–34.40)

14.82 (14.62–15.01)

28.68 (28.32–29.08)

HR, 95% CIa

Ref.

5.84 (5.22–6.54)

7.61 (6.80–8.51)

17.49 (15.64–19.55)

NA

Survival ratesb

     

 1-year, 95% CI

97.42 (96.97–97.87)

83.40 (83.04–83.76)

81.91 (81.41–82.40)

57.52 (57.05-58.00)

74.07 (73.81–74.33)

 2-year, 95% CI

94.81 (94.07–95.55)

69.13 (68.61–69.65)

60.92 (60.20-61.66)

33.58 (33.06–34.10)

54.89 (54.56–55.23)

 3-year, 95% CI

91.81 (90.74–92.90)

59.88 (59.26–60.51)

48.01 (47.17–48.88)

22.51 (22.00-23.05)

44.21 (43.83–44.60)

 4-year, 95% CI

89.55 (88.18–90.95)

54.26 (53.54–54.98)

39.81 (38.86–40.79)

16.82 (16.29–17.37)

37.97 (37.54–38.40)

 5-year, 95% CI

85.07 (82.77–87.44)

49.34 (48.46–50.24)

35.56 (34.48–36.67)

13.15 (12.57–13.76)

33.53 (33.04–34.03)

  1. Abbreviations: CI, confidence interval; HR, hazard ratio; NA, not applicable; OS, overall survival.
  2. a HRs and 95% CIs were obtained using a univariable Cox proportional-hazard model.
  3. b Survival rates were estimated using the Kaplan–Meier (KM) method